Clinical Trial for PB-119 in Healthy Subjects (Phase I)

NCT02084251 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of a new investigational drug called PB-119 in healthy adult volunteers.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design double-blind treatment study

Participants 70 people

Who can join Ages 18–45 · all sexes Healthy volunteers accepted.

Timeline Started 2014-02 · est. completion 2014-11

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT02084251 ↗

Description as written by the study sponsor.

GLP-1 analogues have been widely used because of their unique advantages (no risk of hypoglycemia) due to their glucose dependent mechanism. Due to the short half-life of peptide in plasma, peptides have to be administered frequently (i.e. BID for Byetta, with Exenatide as API).To improve the patients compliance and reduce potential adverse events associated with GLP-1 analogues, a long acting GLP-1 analogue (PB-119), which may be administered once weekly, was developed by PegBio Inc. In order to provide rational for dosage range to be studied in Phase Ib, the safety profile, tolerance, and pharmacokinetic behavior of PB-119 in healthy subjects will be studied in this randomized, controlled dose escalating trial.

Treatments tested

PB-119 Drug

Main thing measured	Safety/Adverse Event Outcome Measure
Sponsor	PegBio Co., Ltd.
Conditions studied	Type II Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02084251 ↗